title: Management of Endometrial Hyperplasia: A Survey of Members of the Korean Gynecologic Oncology Group.
abstract: OBJECTIVE
  This study aimed to investigate the current management of endometrial hyperplasia (EH) in Korea.
  
  
  METHODS
  This was an electronic survey, which included 40 questions, that was distributed to the members of the Korean Gynecologic Oncology Group in 2014.
  
  
  RESULTS
  In total, 50 (69%) of 72 members responded to the survey. The oral progestogens were the most popular choices for managing EH without atypia (simple hyperplasia(SH), 64%; complex hyperplasia (CH), 52%). In the case of CH with atypia, most of the gynecologist respondents would perform hysterectomy (95.9%). For fertility preservation, the oral progestogens were the most popular choices (SH, 75.5%; CH, 56.3%), followed by the levonorgestrel-releasing intrauterine system (LNG-IUS). More than 70% of the respondents reported use of dilatation and curettage as a follow-up method.
  
  
  CONCLUSIONS
  Our survey results show that most of Korean gynecologic oncologists still prefer oral progestogens for conservative management of EH, notwithstanding the many successful reports on the LNG-IUS. As a follow-up evaluation method, dilatation and curettage is mostly used. To identify the optimum therapy, a randomized controlled trial comparing the LNG-IUS with continuous oral progestogens is required. Furthermore, a large-scale prospective study to confirm the most reliable technique for follow-up evaluation is necessary.
authors.affiliation: *Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University; †Department of Obstetrics and Gynecology, Seoul National University Hospital; ‡Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University, Seoul; §Department of Obstetrics and Gynecology, Soonchunhyang University Cheonan Hospital, Cheonan; ∥Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu; and ¶Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, Korea.
authors.forename: Mi Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Seok Ju
authors.initials: SJ
authors.lastname: Seong
authors.forename: Jae-Weon
authors.initials: JW
authors.lastname: Kim
authors.forename: Duk-Soo
authors.initials: DS
authors.lastname: Bae
authors.forename: Seob
authors.initials: S
authors.lastname: Jeon
authors.forename: Sang-Hoon
authors.initials: SH
authors.lastname: Kwon
authors.forename: Taek Sang
authors.initials: TS
authors.lastname: Lee
mesh_terms: D003131:Combined Modality Therapy; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D019468:Disease Management; D004714:Endometrial Hyperplasia / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D056910:Republic of Korea
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel